1. Scrip
  2. >>Focus On Asia

Global First Approval For Daiichi’s EZH1/2 Inhibitor Valemetostat In Japan

Ozoralizumab Also Gets First Nod

 
• By Lisa Takagi

Japan has granted to the first approval worldwide to Daiichi Sankyo’s dual EZH1/2 inhibitor valemetostat, for the treatment of adult T-cell leukemia/lymphoma. Taisho’s trivalent anti-TNFα nanobody ozoralizumab also received its global first approval, as part a large new batch of regulatory nods in the country.

The First dual inhibitor for EZH 1/2 approved for ATL
First dual inhibitor for EZH 1/2 approved for ATL • Source: Shutterstock

Japan has given the first approval anywhere globally to Daiichi Sankyo Co., Ltd.’s dual inhibitor of EZH1 (enhancer of zeste homolog 1) and EZH2 Ezharmia (valemetostat; DS-3201), for the treatment of relapsed/refractory adult T-cell leukemia/lymphoma (ATL), putting it in a good position to be the first drug in the class to reach the market. 

It also marks another milestone for Daiichi's strategic pivot to oncology as a core focus, which has now resulted in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Pharma’s Space Trails Entering Transformative Era - Keytruda’s Been There

 
• By Anju Ghangurde

Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 
• By Dexter Jie Yan

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.